On January 6, 2023, Sanofi delivered written notice to Regulus Therapeutics Inc. of SanofiÆs election to terminate in its entirety the second amended and restated collaboration and license agreement entered into between Sanofi and the Company on February 4, 2014, as amended (the ôAgreementö). Previously, on July 12, 2022, the Company received notification from Sanofi of its decision to terminate the Phase 2 clinical study of lademirsen for the treatment of Alport syndrome for failure to meet SanofiÆs pre-defined futility criteria. Regulus was notified at that time, that Sanofi was evaluating other opportunities for the program in other indications and according to Sanofi, the decision to terminate the study did not stem from any safety issues.

In accordance with the Agreement, the termination will become effective on February 5, 2023, which is 30 days following the date of delivery of the notice by Sanofi. Under the terms of the Agreement, Regulus had granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi assumed all responsibilities and obligations for developing and commercializing each of miR-21 programs, including lademirsen for the treatment of Alport Syndrome.

Lademirsen was the only product candidate from the collaboration advanced against miR-21 into the clinic. In addition, under the Agreement Sanofi had opt-in rights to preclinical program targeting miR-221/222 for oncology indications. Under the terms of the Agreement, Regulus was eligible to receive $25.0 million in further development milestone payments in the event the Phase 2 clinical study of lademirsen achieved its primary clinical endpoint or upon SanofiÆs election to advance the program into later stages of clinical development.

In addition, in the event Sanofi exercised its opt-in rights to the miR221/222 program, Regulus was eligible to receive milestone payments related to the development and commercialization of miR-221/222 for hepatocellular carcinoma of up to $38.8 million for proof-of-concept option exercise fees, $25.0 million for clinical milestones and up to $130.0 million for regulatory and commercial milestones. Regulus was also eligible to receive royalties based on a percentage of net sales of any products from the miR-221/222 program.